Literature DB >> 20890226

SOX10 expression in superficial spreading and nodular malignant melanomas.

Margrét Agnarsdóttir1, Linda Sooman, Asa Bolander, Sara Strömberg, Elton Rexhepaj, Michael Bergqvist, Fredrik Ponten, William Gallagher, Johan Lennartsson, Simon Ekman, Mathias Uhlen, Håkan Hedstrand.   

Abstract

SOX10 is a transcription factor expressed in nerve cells and melanocytes. The aim of this study was to investigate the protein expression pattern of SOX10 in malignant melanoma tumors and to analyze whether the results correlated with clinical parameters and the proliferation marker Ki-67. Furthermore, proliferation and migration were analyzed in three different cell lines employing SOX10 small interfering RNA-mediated silencing. Expression patterns were determined in 106 primary tumors and 39 metastases in addition to 16 normal skin samples and six benign nevi employing immunohistochemistry and tissue microarrays. The immunohistochemical staining was evaluated manually and with an automated algorithm. SOX10 was strongly expressed in the benign tissues, but for the malignant tumors superficial spreading melanomas stained stronger than nodular malignant melanomas (P=0.008). The staining intensity was also inversely correlated with T-stage (Spearman's ρ=-0.261, P=0.008). Overall survival and time to recurrence were significantly correlated with SOX10 intensity, but not in multivariate analysis including T-stage. With the automated algorithm there was an inverse correlation between the SOX10 staining intensity and the proliferation marker, Ki-67 (ρ=-0.173, P=0.02) and a significant difference in the intensity signal between the benign tissues, the primary tumors and the metastases where the metastases stained the weakest (P≤0.001). SOX10 downregulation resulted in variable effects on proliferation and migration rates in the melanoma cell lines. In conclusion, the SOX10 intensity level differed depending on the tissue studied and SOX10 might have a role in survival. No conclusion regarding the role of SOX10 for in-vitro proliferation and migration could be drawn.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20890226     DOI: 10.1097/CMR.0b013e3283403ccd

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  16 in total

1.  Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma.

Authors:  Olga Shakhova; Daniel Zingg; Simon M Schaefer; Lisette Hari; Gianluca Civenni; Jacqueline Blunschi; Stéphanie Claudinot; Michal Okoniewski; Friedrich Beermann; Daniela Mihic-Probst; Holger Moch; Michael Wegner; Reinhard Dummer; Yann Barrandon; Paolo Cinelli; Lukas Sommer
Journal:  Nat Cell Biol       Date:  2012-07-08       Impact factor: 28.824

2.  Gene expression profiling using nanostring digital RNA counting to identify potential target antigens for melanoma immunotherapy.

Authors:  Rachel E Beard; Daniel Abate-Daga; Shannon F Rosati; Zhili Zheng; John R Wunderlich; Steven A Rosenberg; Richard A Morgan
Journal:  Clin Cancer Res       Date:  2013-09-10       Impact factor: 12.531

3.  Enhanced SOX10 and KIT expression in cutaneous melanoma.

Authors:  Lars Rönnstrand; Bengt Phung
Journal:  Med Oncol       Date:  2013-06-26       Impact factor: 3.064

4.  SOX10 promotes melanoma cell invasion by regulating melanoma inhibitory activity.

Authors:  Saskia A Graf; Christian Busch; Anja-Katrin Bosserhoff; Robert Besch; Carola Berking
Journal:  J Invest Dermatol       Date:  2014-03-07       Impact factor: 8.551

5.  SOXs in human prostate cancer: implication as progression and prognosis factors.

Authors:  Wei-de Zhong; Guo-qiang Qin; Qi-shan Dai; Zhao-dong Han; Shan-ming Chen; Xiao-hui Ling; Xin Fu; Chao Cai; Jia-hong Chen; Xi-bin Chen; Zhuo-yuan Lin; Ye-han Deng; Shu-lin Wu; Hui-chan He; Chin-lee Wu
Journal:  BMC Cancer       Date:  2012-06-15       Impact factor: 4.430

6.  SOX10 ablation arrests cell cycle, induces senescence, and suppresses melanomagenesis.

Authors:  Julia C Cronin; Dawn E Watkins-Chow; Art Incao; Joanne H Hasskamp; Nicola Schönewolf; Lauren G Aoude; Nicholas K Hayward; Boris C Bastian; Reinhard Dummer; Stacie K Loftus; William J Pavan
Journal:  Cancer Res       Date:  2013-08-01       Impact factor: 12.701

7.  Sox10 controls migration of B16F10 melanoma cells through multiple regulatory target genes.

Authors:  Ikjoo Seong; Hyun Jung Min; Jung-Hyun Lee; Chang-Yeol Yeo; Dong Min Kang; Eok-Soo Oh; Eun Sook Hwang; Jaesang Kim
Journal:  PLoS One       Date:  2012-02-21       Impact factor: 3.240

8.  Bioinformatic identification of proteins with tissue-specific expression for biomarker discovery.

Authors:  Ioannis Prassas; Caitlin C Chrystoja; Shalini Makawita; Eleftherios P Diamandis
Journal:  BMC Med       Date:  2012-04-19       Impact factor: 8.775

Review 9.  Emerging clinical applications of selected biomarkers in melanoma.

Authors:  Michael T Tetzlaff; Carlos A Torres-Cabala; Penvadee Pattanaprichakul; Ronald P Rapini; Victor G Prieto; Jonathan L Curry
Journal:  Clin Cosmet Investig Dermatol       Date:  2015-01-30

10.  A texture based pattern recognition approach to distinguish melanoma from non-melanoma cells in histopathological tissue microarray sections.

Authors:  Elton Rexhepaj; Margrét Agnarsdóttir; Julia Bergman; Per-Henrik Edqvist; Michael Bergqvist; Mathias Uhlén; William M Gallagher; Emma Lundberg; Fredrik Ponten
Journal:  PLoS One       Date:  2013-05-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.